Advanced Enzyme Technologies Limited (NSE: ADVENZYMES | BSE: 540025)
Source: Advanced Enzyme Technologies Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Advanced Enzyme Technologies Limited (AETL) is a research-driven, integrated global leader in the development, manufacturing, and marketing of proprietary enzyme products and probiotics. Operating at the intersection of biotechnology, green chemistry, and sustainable industrial processing, your Company commercialises over 400 proprietary products derived from a biological library of more than 68 indigenous enzymes and probiotics.
- Human Healthcare & Pharma/API Portfolio: Key offerings include Serratiopeptidase (anti-inflammatory enzyme contributing 23% of consolidated sales, generating ₹173.20 Crores in FY26), fungal lactase, fungal lipase, proteases, and proprietary probiotic strains (such as Bacillus subtilis SEBtilis™ and Bacillus clausii SEBclausii™) targeting gut health, metabolic balance, and immunity.
- Animal Nutrition & Feed Additives: Customised carbohydrase blends, phytases, toxin binders, and probiotic formulations (DigeSEB Super Pet™) that enhance nutrient digestibility, improve feed conversion ratios (FCR), and replace antibiotic growth promoters in livestock.
- Food & Non-Food Bio-Processing: Enzymatic solutions for baking (crumb softening, dough conditioning), brewing and malting, dairy processing (lactase for lactose-free milk, cheese rennets), fruit juice clarification, grain starch conversion, textile eco-bleaching, leather bating, and paper pulp processing.
- Biocatalysts for Green Chemistry: Specialized engineered enzymes designed to replace conventional chemical catalysts in active pharmaceutical ingredient (API) synthesis, fine chemical production, and organic synthesis, reducing solvent consumption and effluent loads.
📋 Quick Facts / Company Snapshot: Advanced Enzyme Technologies Limited (NSE: ADVENZYMES | BSE: 540025)
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Advanced Enzyme Technologies Limited |
| Corporate Identity Number (CIN) | L24200MH1989PLC051018 |
| International Securities Identification Number (ISIN) | INE837H01020 |
| Stock Exchange Listing | NSE: ADVENZYMES | BSE: 540025 |
| Date of Incorporation & Legacy | Incorporated on March 15, 1989 (as Advanced Biochemicals Private Limited; renamed to Advanced Enzyme Technologies Limited in 2005) |
| Founders & Key Founding Figures | Mr. Vasant L. Rathi & Late Mr. Chandrakant L. Rathi |
| Registered Office & Corporate HQ | A-Wing, Sun Magnetica, 5th Floor, LIC Service Road, Louiswadi, Thane (West) – 400604, Maharashtra, India |
| Telephone & Investor Email | +91-22-4170 3200 | info@advancedenzymes.com / investor.grievances@advancedenzymes.com |
| Chairman & Non-Executive Director | Mr. Vasant L. Rathi |
| Whole-time Director | Mr. Mukund M. Kabra |
| Key Managerial Personnel (KMP) | Mr. Beni Prasad Rauka (Group CFO) | Mr. Sanjay Basantani (Company Secretary & Head – Legal) |
| Promoter Group Shareholding | 43.26% (held across Indian and Foreign Promoter entities) |
| Industry & NIC Classification | Biotechnology / Speciality Chemicals / Enzymes & Probiotics (NIC Code: 21001) |
| Workforce Count & Attrition Rate | 401 Employees & 362 Workers (763 total standalone workforce; 410 permanent employees on rolls); Employee Turnover Rate: 14.11% |
| Manufacturing Infrastructure | 9 world-class manufacturing facilities globally (4 primary Indian plants at Sinnar, Satpur, Vasind, and Pithampur SEZ, plus subsidiary units at Ongole and Musalgaon; 2 US facilities at Chino, CA) |
| Credit Rating & Agency | ICRA: [ICRA]AA- (Stable) for Long-Term Cash Credit; [ICRA]AA- (Stable) / [ICRA]A1+ for Long/Short-Term Unallocated Limits; [ICRA]A1+ for Short-Term Non-Fund Limits |
| Statutory, Secretarial & Internal Auditors | Statutory: MSKA & Associates LLP | Secretarial: Shiv Hari Jalan & Co. | Internal: Aneja Associates |
| Registrar & Share Transfer Agent (RTA) | MUFG Intime India Private Limited (formerly Link Intime India Private Limited), Vikhroli (West), Mumbai |
🏢 The Corporate Identity: Advanced Enzyme Technologies Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Advanced Enzyme Technologies Limited (AETL) is a research-driven, integrated global leader in the development, manufacturing, and marketing of proprietary enzyme products and probiotics. Operating at the intersection of biotechnology, green chemistry, and sustainable industrial processing, your Company commercialises over 400 proprietary products derived from a biological library of more than 68 indigenous enzymes and probiotics. AETL spans the complete enzymology value chain—from strain development, genetic engineering, and microbial fermentation to large-scale downstream processing, formulation, and global market distribution.
The Company operates across four primary business verticals: Human Nutrition, Animal Nutrition, Industrial Bio-Processing (comprising Food Processing and Non-Food Processing), and Specialised Manufacturing. By substituting conventional chemical catalysts and high-energy thermal processes with bio-catalytic enzymatic solutions, AETL enables industrial customers to reduce energy consumption, lower chemical effluents, improve process yields, and transition toward sustainable, low-carbon manufacturing. AETL maintains a strong dual revenue engine split equally between international export markets (50% of revenue) and domestic Indian sales (50% of revenue).
- Integrated Bio-Manufacturing Backbone: Operates over 500 cubic metres of fermentation capacity supported by advanced submerged and solid-state fermentation infrastructure across India and the United States.
- High Entry Barrier Business Model: Built upon three decades of proprietary strain banks, proprietary enzyme libraries, complex regulatory filings (including US FDA GRAS and EFSA dossiers), and deep application-level technical know-how.
- B2B Foundation with Emerging B2C Wellness Engine: While maintaining a dominant B2B supplier relationship with global pharmaceutical, nutraceutical, and food processing leaders, AETL is expanding its direct-to-consumer footprint via its consumer wellness brand WELLFA, managed through its dedicated subsidiary Advanced Nutrazyme Private Limited.
The Founders, Promoters & Their Legacy
The scientific and entrepreneurial foundation of Advanced Enzyme Technologies Limited was laid by Mr. Vasant L. Rathi and his late brother, Mr. Chandrakant L. Rathi. Pioneering the commercial production of industrial enzymes in India during an era when the domestic market was entirely dependent on imported chemical catalysts, the founders transformed a regional pioneer into a globally recognized enzyme multinational.
Mr. Vasant L. Rathi, Chairman and Non-Executive Director, brings over four decades of global enzymology and corporate management experience. Based in the United States, Mr. Rathi has spearheaded AETL’s international expansion, overseeing key strategic acquisitions including Cal-India Foods International (Specialty Enzymes and Biotechnologies) and AST Corp, thereby embedding the Company deeply into the North American nutraceutical and healthcare supply chains. Whole-time Director Mr. Mukund M. Kabra leads operational management, strategic execution, capacity planning, and business diversification across global business units.
- Promoter Group Holding: As of March 31, 2026, the Promoter and Promoter Group holds 43.26% of the Company’s equity share capital, comprising 1.95% Indian promoter holdings and 41.31% foreign promoter holdings (held principally through Mr. Vasant Rathi and family trusts).
- Institutional Alignment: Prominent long-term institutional shareholders include Nalanda India Equity Fund Limited (8.46%) and OrbiMed Asia III Mauritius FVCI Limited (12.07%).
The Journey: Corporate History & Key Milestones
Incorporated in 1989 as Advanced Biochemicals Private Limited, the Company initiated its manufacturing journey by commissioning its first commercial fermentation facility at Sinnar, Maharashtra, in 1994. The early 2000s marked a decade of rapid scientific validation, with the Department of Scientific and Industrial Research (DSIR) granting formal recognition to R&D facilities in Thane and Sinnar in 2001, followed by the filing of the Company’s initial patents in 2004.
In 2005, the corporate entity was renamed Advanced Enzyme Technologies Limited. The subsequent two decades were defined by aggressive global expansion, regulatory dossier registrations, and inorganic acquisitions that expanded the Company’s technological footprint across continents.
- 2011–2012 (North American Inorganic Scale): Acquired Cal-India Foods International (USA) and Advanced Supplementary Technologies Corporation (AST Corp, USA), securing direct distribution networks for branded nutraceutical enzymes across the Americas.
- 2016 (Capital Markets Listing & Fermentation Scaling): Successfully listed on the BSE and NSE via an Initial Public Offering (IPO) while consolidating a controlling 70% stake in JC Biotech Private Limited, expanding API-grade enzyme fermentation capacity in Ongole, Andhra Pradesh.
- 2017 (European Biotechnology Platform): Established Advanced Enzymes Europe B.V. in the Netherlands and acquired 100% of evoxx technologies GmbH in Germany, gaining cutting-edge strain development, directed evolution, and biocatalysis research assets.
- 2021–2023 (Speciality Manufacturing & Bio-Sourcing Expansion): Acquired a 51% controlling stake in SciTech Specialities Private Limited (effervescent delivery platforms) and a 50% stake in Saiganesh Enzytech Solutions Private Limited (papain extraction from papaya latex).
- 2025–2026 (B2C Launch & Regulatory Filings): Incorporated Advanced Nutrazyme Private Limited to house the WELLFA consumer brand; established Starya Labs Inc. as an independent US testing facility; filed 3 new patent applications and 3 GRAS dossiers with the US FDA.
The Corporate Umbrella & Group Structure
Advanced Enzyme Technologies Limited operates as an integrated corporate group comprising 13 direct and step-down subsidiaries spanning India, the United States, the Netherlands, and Germany. The Group structure balances low-cost indigenous fermentation and chemical synthesis in India with high-margin international marketing, technical customer support, and advanced enzyme engineering in Europe and North America.
- Domestic Operating Subsidiaries: Advanced Bio-Agro Tech Limited (60% stake; animal nutrition focus), JC Biotech Private Limited (95.72% stake; bio-pharmaceuticals & enzyme manufacturing), SciTech Specialities Private Limited (51% stake; effervescent delivery formats), Advanced EnzyTech Solutions Limited (100% stake; non-food industrial processing), Saiganesh Enzytech Solutions Private Limited (50% stake; papain extraction), and Advanced Nutrazyme Private Limited (100% stake; B2C nutrition & wellness).
- International Holding & Operating Units: Advanced Enzymes USA Inc. (100% direct US holding company) overseeing Cal-India Foods International, Advanced Supplementary Technologies Corporation, Enzyme Innovation Inc., and Starya Labs Inc.; Advanced Enzymes Europe B.V. (100% Netherlands unit) holding 100% of evoxx technologies GmbH (Germany).
⚙️ The Business Engine: Advanced Enzyme Technologies Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
AETL classifies its operational performance across four major business verticals. During FY 2025-26, Consolidated Revenue from Operations expanded by 17.09% year-on-year to reach ₹745.76 Crores (compared to ₹636.91 Crores in FY 2024-25), driven by robust volume growth across Human Nutrition, Food Processing, and Animal Nutrition.
| Business Vertical | FY 2025-26 Revenue (₹ Crores) | FY 2024-25 Revenue (₹ Crores) | % Share of Total Revenue (FY 2025-26) | Latest YoY (%) |
|---|---|---|---|---|
| Human Nutrition | 467.40 | 405.30 | 62.68% | +15.32% |
| Animal Nutrition | 94.60 | 76.00 | 12.68% | +24.47% |
| Industrial Bio-Processing | 117.60 | 101.80 | 15.77% | +15.52% |
| Food Processing | 96.70 | 80.90 | 12.97% | +19.53% |
| Non-Food Processing | 20.90 | 20.80 | 2.80% | +0.48% |
| Specialised Manufacturing | 66.20 | 53.90 | 8.87% | +22.82% |
| Total Revenue from Operations | 745.80 | 636.90 | 100.00% | +17.10% |
Human Nutrition remains the foundational growth engine, accounting for 62.68% of total consolidated sales. The vertical recorded revenues of ₹467.40 Crores in FY 2025-26, supported by sales of active pharmaceutical ingredients (APIs) such as Serratiopeptidase alongside specialty digestive and systemic enzyme blends. Animal Nutrition recorded the fastest organic expansion, surging 24.47% to ₹94.60 Crores due to higher commercial adoption of feed additive enzymes and probiotics across poultry and cattle segments in domestic and South-East Asian markets.
The Product & Service Catalog (with Operational KPIs, Order Book & Customer Concentration)
AETL’s multi-faceted product portfolio addresses critical processing challenges across healthcare, agri-nutrition, food manufacturing, and industrial bio-catalysis:
- Human Healthcare & Pharma/API Portfolio: Key offerings include Serratiopeptidase (anti-inflammatory enzyme contributing 23% of consolidated sales, generating ₹173.20 Crores in FY26), fungal lactase, fungal lipase, proteases, and proprietary probiotic strains (such as Bacillus subtilis SEBtilis™ and Bacillus clausii SEBclausii™) targeting gut health, metabolic balance, and immunity.
- Animal Nutrition & Feed Additives: Customised carbohydrase blends, phytases, toxin binders, and probiotic formulations (DigeSEB Super Pet™) that enhance nutrient digestibility, improve feed conversion ratios (FCR), and replace antibiotic growth promoters in livestock.
- Food & Non-Food Bio-Processing: Enzymatic solutions for baking (crumb softening, dough conditioning), brewing and malting, dairy processing (lactase for lactose-free milk, cheese rennets), fruit juice clarification, grain starch conversion, textile eco-bleaching, leather bating, and paper pulp processing.
- Biocatalysts for Green Chemistry: Specialized engineered enzymes designed to replace conventional chemical catalysts in active pharmaceutical ingredient (API) synthesis, fine chemical production, and organic synthesis, reducing solvent consumption and effluent loads.
- Operational KPIs & Capacity Utilisation: Across its combined Indian and US fermentation assets, AETL operates over 500+ m³ of fermentation capacity. Overall total capacity utilisation across group manufacturing assets averaged ~70% during FY 2025-26.
- Raw Material Sourcing & Customer Concentration: Raw material inputs primarily comprise agricultural substrates (soy meal, wheat bran, starch), organic salts, solvents, and packaging materials. Sourcing is balanced between domestic agricultural suppliers and imported specialty chemicals. In compliance with Ind AS 108 disclosures, no single external customer accounted for 10% or more of total consolidated revenue in FY 2025-26 or FY 2024-25, demonstrating low customer concentration risk across its 700+ global customer base.
The Names You Know: Key Brands & Flagship Portfolio
| Brand / Product Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Serratiopeptidase | Pharma / API (Human Nutrition) | Flagship anti-inflammatory enzyme API used globally in pain management and tissue healing formulations. |
| DigeSEB® / DigeSEB Super Pet™ | Nutraceuticals & Animal Health | Proprietary digestive enzyme complex for human gut health and companion animal nutrition. |
| SEBtilis™ & SEBclausii™ | Probiotics (Human & Animal) | US FDA GRAS-affirmed spore-forming probiotic strains for metabolic and intestinal health. |
| ImmunoSEB™ & ProbioSEB CSC3™ | Healthcare & Life Sciences | Clinically evaluated systemic enzyme and probiotic formulations targeting immune system response. |
| WELLFA | Consumer Wellness (B2C Segment) | Direct-to-consumer nutritional supplement brand offering science-backed effervescent and oral formulations. |
Mapping the Domestic & Global Reach (India vs. Exports)
AETL serves over 700 customers across more than 45 countries spanning 5 continents. The business maintains an evenly balanced geographical structure, mitigating single-region macroeconomic vulnerabilities.
| Geographic Region | FY 2025-26 Revenue (₹ Crores) | FY 2024-25 Revenue (₹ Crores) | % Share of Total Revenue (FY 2025-26) | Latest YoY (%) |
|---|---|---|---|---|
| India (Domestic) | 372.70 | 290.50 | 49.97% | +28.30% |
| International (Exports & Overseas) | 373.10 | 346.40 | 50.03% | +7.71% |
| Americas | 219.20 | 236.70 | 29.39% | -7.39% |
| Europe | 39.80 | 33.50 | 5.34% | +18.81% |
| Asia (excluding India) | 90.40 | 58.90 | 12.12% | +53.48% |
| Rest of the World | 23.60 | 17.20 | 3.16% | +37.21% |
| Total Revenue | 745.80 | 636.90 | 100.00% | +17.10% |
Domestic Indian revenues expanded dynamically by 28.29% in FY 2025-26 to reach ₹372.70 Crores, buoyed by heightened demand for pharma enzymes, food bio-processing solutions, and effervescent nutraceutical products. Overseas revenues reached ₹373.10 Crores, led by a 53.48% surge in non-India Asian markets (reaching ₹90.40 Crores) and steady growth in Europe (up 18.81% to ₹39.80 Crores), which offset temporary tariff-related discretionary slowdowns in the Americas.
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
The Company operates a globally distributed footprint of 9 certified manufacturing plants and 7 R&D centres across India, the US, and Germany:
- Primary Indian Fermentation & Processing Assets:
- Sinnar Facility (MIDC Malegaon, Sinnar, Nashik, Maharashtra): Primary large-scale fermentation, enzyme recovery, and purification complex.
- Satpur Facility (MIDC Satpur, Nashik, Maharashtra): Formulation, blending, and bio-processing facility.
- Vasind Facility (Thane, Maharashtra): Specialised processing unit.
- Pithampur SEZ Facility (Dhar, Indore, Madhya Pradesh): Second major commercial fermentation plant dedicated to export-oriented products.
- Ongole Facility (APIIC Growth Centre, Ongole, Andhra Pradesh): JC Biotech’s dedicated fermentation plant for anti-inflammatory enzyme APIs.
- Sinnar Unit I & II (STICE Musalgaon, Nashik, Maharashtra): SciTech’s specialised effervescent sachet and tablet manufacturing plants.
- International Processing & Testing Assets:
- Chino Facilities (Yorba Avenue & Murrieta St., Chino, CA, USA): Custom enzyme blending, formulation, packaging, and regulatory support units catering to North and Latin America.
- Starya Labs (Tustin, CA, USA): ISO-17025 accredited analytical testing laboratory for enzymes and probiotics.
- Global R&D Ecosystem: Operates 7 specialized R&D centres (5 in India, 1 in California, USA, and 1 in Monheim am Rhein, Germany at evoxx technologies). To further expand biocatalysis and strain engineering capabilities, AETL is constructing a new large-scale state-of-the-art R&D centre in Nashik, scheduled for operational commissioning in the second half of FY 2026-27.
📊 The Financial Health: Advanced Enzyme Technologies Financial Statements & Numbers Simplified
Multi-Year Financial Highlights (₹ in Crores)
| Financial Metric | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | Latest YoY (%) |
|---|---|---|---|---|---|---|
| Revenue from Operations | 745.80 | 636.90 | 623.90 | 540.60 | 529.40 | +17.10% |
| Net Sales (excluding Export Incentives) | 745.76 | 636.91 | 623.50 | 540.40 | 528.90 | +17.09% |
| EBITDA (excl. Other Income) | 229.10 | 194.40 | 204.50 | 156.40 | 201.40 | +17.85% |
| EBITDA Margin (%) | 30.72% | 30.52% | 32.78% | 28.93% | 38.04% | – |
| Operating Profit (EBIT) | 189.00 | 157.90 | 169.30 | 121.40 | 166.50 | +19.70% |
| Profit Before Tax (PBT) | 232.50 | 187.40 | 188.00 | 140.40 | 171.10 | +24.07% |
| Profit After Tax (PAT – Total Group) | 173.60 | 134.00 | 137.10 | 103.90 | 123.80 | +29.55% |
| PAT Attributable to Parent Owners | 168.70 | 131.10 | 133.30 | 105.60 | 119.60 | +28.68% |
| PAT Margin (%) | 23.28% | 21.04% | 21.98% | 19.22% | 23.38% | – |
| Shareholders’ Fund (Net Worth) | 1,632.00 | 1,420.90 | 1,324.10 | 1,235.10 | 1,088.60 | +14.86% |
| Total Debt | 20.50 | 21.50 | 25.10 | 13.20 | 10.90 | -4.65% |
| Basic EPS (₹ per share of FV ₹2) | 15.08 | 11.72 | 11.92 | 9.45 | 10.70 | +28.67% |
| Return on Equity (ROE %) | 10.31% | 9.12% | 11.00% | 9.00% | 12.00% | – |
| Return on Capital Employed (ROCE %) | 10.91% | 10.35% | 13.00% | 10.00% | 16.00% | – |
| Return on Invested Capital (ROIC %) | 16.00% | 15.00% | 18.00% | 15.00% | 26.00% | – |
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
| Consolidated Statement of Profit & Loss Line Item | FY 2025-26 (₹ Crores) | FY 2024-25 (₹ Crores) | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 745.76 | 636.91 | +17.09% |
| Other Income | 34.83 | 33.04 | +5.42% |
| Total Income | 780.59 | 669.95 | +16.51% |
| Expenses: | |||
| Cost of Materials Consumed | 194.31 | 161.96 | +19.97% |
| Changes in Inventories of Finished Goods, WIP and Stock-in-Trade | -1.36 | -10.10 | -86.53% |
| Employee Benefits Expense | 162.29 | 141.54 | +14.66% |
| Finance Costs | 2.63 | 3.56 | -26.12% |
| Depreciation and Amortisation Expense | 40.09 | 36.56 | +9.66% |
| Other Expenses | 161.45 | 149.07 | +8.30% |
| Total Expenses | 559.41 | 482.59 | +15.92% |
| EBITDA (excluding Other Income) | 229.10 | 194.40 | +17.85% |
| Operating Profit (EBIT) | 189.00 | 157.90 | +19.70% |
| Profit Before Exceptional Items & Tax | 221.18 | 187.36 | +18.05% |
| Exceptional Items (Net Credit / -Expense) | -11.36 | 0.00 | N/M |
| Profit Before Tax (PBT) | 232.54 | 187.36 | +24.11% |
| Tax Expense: | |||
| Current Tax | 56.57 | 49.56 | +14.14% |
| Minimum Alternate Tax (MAT) Credit Entitlement | 0.32 | -0.24 | N/M |
| Deferred Tax (Credit) / Charge | 2.17 | 3.86 | -43.78% |
| Tax Adjustment for Earlier Years | -0.12 | 0.22 | N/M |
| Total Tax Expense | 58.93 | 53.39 | +10.38% |
| Profit for the Year (PAT) | 173.61 | 133.97 | +29.59% |
| Attributable to Owners of Parent | 168.72 | 131.12 | +28.68% |
| Attributable to Non-Controlling Interest | 4.89 | 2.86 | +70.98% |
The P&L analysis underscores strong operational execution. Revenue expanded 17.09% to ₹745.76 Crores, while EBITDA grew 17.09% to ₹229.10 Crores, maintaining an industry-leading EBITDA margin of 30.72%. Total Group PAT surged 29.59% to ₹173.61 Crores, benefited by an exceptional net credit of ₹11.36 Crores. This net exceptional gain comprised a ₹16.14 Crore reversal of prior legal provisions (following a favorable ruling by the US Court of Appeals in favor of AST Corp) offset by a ₹4.78 Crore one-time provision for employee benefit adjustments pursuant to India’s Labour Code consolidation.
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
| Consolidated Balance Sheet Line Item | As at March 31, 2026 (₹ Crores) | As at March 31, 2025 (₹ Crores) | Latest YoY (%) |
|---|---|---|---|
| I. ASSETS | |||
| 1. Non-Current Assets | |||
| (a) Property, Plant and Equipment | 275.83 | 292.94 | -5.84% |
| (b) Capital Work-in-Progress (CWIP) | 51.17 | 21.69 | +135.92% |
| (c) Goodwill | 369.46 | 333.44 | +10.80% |
| (d) Other Intangible Assets | 46.92 | 52.29 | -10.27% |
| (e) Intangible Assets Under Development | 0.00 | 0.02 | -100.00% |
| (i) Non-Current Investments | 0.06 | 0.07 | -14.29% |
| (ii) Non-Current Loans | 0.10 | 0.07 | +42.86% |
| (iii) Other Non-Current Financial Assets | 9.68 | 9.92 | -2.42% |
| (g) Deferred Tax Assets (Net) | 4.88 | 10.19 | -52.11% |
| (h) Income Tax Asset (Net) | 23.03 | 17.77 | +29.60% |
| (i) Other Non-Current Assets | 14.05 | 3.09 | +354.69% |
| Total Non-Current Assets | 795.19 | 741.48 | +7.24% |
| 2. Current Assets | |||
| (a) Inventories | 177.28 | 157.31 | +12.69% |
| (i) Current Investments (Mutual Funds & Debt) | 583.83 | 480.26 | +21.57% |
| (ii) Trade Receivables | 145.02 | 115.40 | +25.67% |
| (iii) Cash and Cash Equivalents | 108.76 | 94.23 | +15.42% |
| (iv) Bank Balances other than (iii) above | 7.18 | 13.46 | -46.66% |
| (v) Current Loans | 0.24 | 0.10 | +140.00% |
| (vi) Other Current Financial Assets | 8.63 | 8.05 | +7.20% |
| (c) Other Current Assets | 12.65 | 11.07 | +14.27% |
| Total Current Assets | 1,043.57 | 879.87 | +18.61% |
| TOTAL ASSETS | 1,838.76 | 1,621.35 | +13.41% |
| II. EQUITY AND LIABILITIES | |||
| 1. Equity | |||
| (a) Equity Share Capital | 22.39 | 22.38 | +0.04% |
| (b) Other Equity | 1,609.57 | 1,398.49 | +15.09% |
| Equity Attributable to Owners of Parent | 1,631.96 | 1,420.86 | +14.86% |
| Non-Controlling Interest | 51.17 | 47.81 | +7.03% |
| Total Equity (Net Worth) | 1,683.12 | 1,468.67 | +14.60% |
| 2. Non-Current Liabilities | |||
| (i) Non-Current Borrowings | 7.89 | 9.18 | -14.05% |
| (ii) Non-Current Lease Liabilities | 3.77 | 11.73 | -67.86% |
| (b) Non-Current Provisions | 5.39 | 1.88 | +186.70% |
| (c) Deferred Tax Liabilities (Net) | 31.87 | 33.63 | -5.23% |
| Total Non-Current Liabilities | 48.92 | 56.43 | -13.31% |
| 3. Current Liabilities | |||
| (i) Current Borrowings | 12.64 | 12.35 | +2.35% |
| (ii) Current Lease Liabilities | 7.71 | 6.08 | +26.81% |
| a) Micro and Small Enterprises (MSME) Dues | 6.39 | 4.29 | +48.95% |
| b) Dues to Other Than MSME Enterprises | 33.57 | 15.19 | +121.00% |
| (iv) Other Current Financial Liabilities | 28.51 | 24.35 | +17.08% |
| (b) Other Current Liabilities | 10.49 | 8.53 | +22.98% |
| (c) Current Provisions | 6.39 | 20.86 | -69.37% |
| (d) Current Tax Liabilities (Net) | 1.01 | 4.59 | -78.00% |
| Total Current Liabilities | 106.72 | 96.25 | +10.88% |
| Total Liabilities (Excluding Equity) | 155.64 | 152.68 | +1.94% |
| TOTAL EQUITY AND LIABILITIES | 1,838.76 | 1,621.35 | +13.41% |
Working Capital Cycle & Schedule III Statutory Ratio Explanations
AETL maintains a pristine, net-cash balance sheet. Total debt (combining long-term loans of ₹7.89 Crores and short-term working capital loans of ₹12.64 Crores) stands at ₹20.53 Crores, yielding an almost negligible Net Debt-to-Equity ratio of 0.01x. Liquid treasury assets—comprising mutual fund current investments (₹583.83 Crores), cash and bank balances (₹115.94 Crores), and long-term bank deposits—aggregate to ₹749.84 Crores, ensuring massive capital buffer for future inorganic acquisitions or organic plant expansions.
| Statutory Financial Ratio | FY 2025-26 | FY 2024-25 | Variance (%) | Latest YoY (%) |
|---|---|---|---|---|
| Current Ratio (times) | 9.78 | 9.09 | 7.59% | +7.59% |
| Debt-Equity Ratio (times) | 0.01 | 0.02 | -50.00% | -50.00% |
| Inventory Turnover Ratio (times) | 4.21 | 4.05 | 3.95% | +3.95% |
| Debtors’ Turnover Ratio (times) | 5.14 | 5.52 | -6.88% | -6.88% |
| Trade Payables Turnover Ratio (times) | 18.64 | 32.69 | -42.98% | -42.98% |
| Operating Profit Margin (%) | 30.72% | 30.52% | 0.66% | – |
| Net Profit Margin (%) | 173.61 | 21.04% | 10.65% | – |
| Interest Coverage Ratio (times) | 71.92 | 44.39 | 62.02% | +62.02% |
| Return on Equity (ROE %) | 10.31% | 9.12% | 10.00% | – |
| Return on Capital Employed (ROCE %) | 10.91% | 10.35% | 9.09% | – |
Cash Flow: Tracking the Money Movement
| Consolidated Cash Flow Statement Indicator | FY 2025-26 (₹ Crores) | FY 2024-25 (₹ Crores) | Latest YoY (%) |
|---|---|---|---|
| Profit Before Tax (PBT) | 232.54 | 187.36 | +24.11% |
| Operating Profit Before Working Capital Changes | 236.45 | 214.40 | +10.28% |
| Working Capital Adjustments (Inventories, Trade Receivables & Payables) | -14.55 | -12.23 | +18.97% |
| Cash Generated from Operations | 221.90 | 202.17 | +9.76% |
| Direct Taxes Paid (Net of Refunds) | -65.13 | -59.67 | +9.15% |
| Net Cash Generated from Operating Activities (A) | 156.78 | 142.50 | +10.02% |
| Cash Flows from Investing Activities: | |||
| Purchase of Property, Plant and Equipment (CapEx) & Intangibles | 52.38 | 34.78 | +50.60% |
| Proceeds from Sale of Property, Plant and Equipment | 0.45 | 0.53 | -15.09% |
| (Purchase) / Sale of Current Mutual Fund Investments (Net) | -47.25 | -59.04 | -19.97% |
| Interest Received & Fixed Deposit Movements | 25.05 | 4.20 | +496.43% |
| Net Cash Used in Investing Activities (B) | -74.13 | -89.10 | -16.80% |
| Cash Flows from Financing Activities: | |||
| Proceeds from Issue of Equity Shares (ESOP Exercise) | 0.95 | 0.38 | +150.00% |
| Repayment of Long-Term & Short-Term Borrowings (Net) | -1.01 | -3.58 | -71.79% |
| Finance Costs & Lease Liability Payments | -10.53 | -10.31 | +2.13% |
| Dividends Paid to Shareholders & NCI | -59.78 | -59.03 | +1.27% |
| Net Cash Used in Financing Activities (C) | -70.37 | -72.54 | -2.99% |
| Net Increase / (Decrease) in Cash and Cash Equivalents (A + B + C) | 12.28 | -19.15 | N/M |
| Cash and Cash Equivalents at Beginning of Year | 94.23 | 113.75 | -17.16% |
| Effect of Foreign Exchange Rate Changes on Cash Balances | 2.25 | -0.38 | N/M |
| Cash and Cash Equivalents at End of Year | 108.76 | 94.23 | +15.42% |
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
AETL continues to deploy capital aggressively into capacity creation, pilot plant expansion, and technical dossier creation. Total capital expenditure (additions to Property, Plant, Equipment, and Intangibles) reached ₹52.38 Crores in FY 2025-26 (up from ₹34.78 Crores in FY25), with Capital Work-in-Progress (CWIP) standing at ₹51.17 Crores as of March 31, 2026. CWIP is primarily concentrated in the ongoing construction of the flagship central R&D complex in Nashik and fermentation facility upgrades at Sinnar and Pithampur.
- Consolidated R&D Expenditure: Consolidated R&D investment during FY 2025-26 stood at ₹24.60 Crores (representing 3.30% of Consolidated Net Sales), compared to ₹24.80 Crores (3.86% of Net Sales) in FY 2024-25. On a standalone basis, R&D spending totalled ₹35.59 Crores, representing 7.86% of standalone turnover.
- Foreign Exchange Inflow vs. Outflow (Section 134(3)(m)): On a standalone basis, Total Foreign Exchange Earned from export operations reached ₹143.28 Crores (up from ₹120.44 Crores in FY25). Total Foreign Exchange Outgo for imported raw materials, capital machinery, and overseas technical fees stood at ₹97.02 Crores (up from ₹70.48 Crores in FY25), maintaining a healthy standalone Net Foreign Exchange Surplus of ₹46.26 Crores.
👥 Power & Control: Advanced Enzyme Technologies Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Mr. Vasant L. Rathi | Chairman & Non-Executive Director | 01233447 | Promoter / Non-Independent |
| Mr. Mukund M. Kabra | Whole-time Director | 00148294 | Executive Director |
| Ms. Rasika Rathi | Non-Executive Director | 08300682 | Promoter Group / Non-Independent |
| Mr. Pramod Kasat | Independent Director | 00819790 | Independent Director |
| Mr. Vinodkumar Jajoo | Independent Director | 08224980 | Independent Director |
| Dr. Sunny Sharma | Non-Executive Director | 02267273 | Non-Executive / Non-Independent |
| Ms. Rajshree Patel | Independent Director (upto June 11, 2026) | 08761022 | Independent Director |
| Mr. Nitin Deshmukh | Independent Director | 00060743 | Independent Director |
| Mrs. Vandana Tilak | Independent Director | 10048021 | Independent Director |
| Mr. Pradip Shah | Additional Director (Effective June 12, 2026) | 01225582 | Independent Director |
| Mr. Beni Prasad Rauka | Group Chief Financial Officer (KMP) | KMP | Executive Management |
| Mr. Sanjay Basantani | Company Secretary & Head – Legal (KMP) | KMP | Executive Management |
Who Owns the Stock? Shareholding Pattern
| Category of Shareholder | Number of Equity Shares Held | % of Total Share Capital |
|---|---|---|
| Promoter & Promoter Group | 4,84,20,535 | 43.26% |
| Indian Promoters | 21,81,650 | 1.95% |
| Foreign Promoters (Vasant Rathi & Family Trusts) | 4,62,38,885 | 41.31% |
| Institutional Investors | 3,45,89,210 | 30.71% |
| Foreign Direct Investment (OrbiMed Asia III) | 1,35,09,522 | 12.07% |
| Foreign Portfolio Investors (Nalanda India, etc.) | 1,50,22,572 | 13.42% |
| Alternate Investment Funds (AIFs) | 38,92,110 | 3.48% |
| Mutual Funds | 21,62,016 | 1.93% |
| Public & Non-Institutional Shareholders | 2,89,17,055 | 26.03% |
| Resident Individuals | 2,21,82,044 | 19.82% |
| HUFs, NRIs, Bodies Corporate, Trusts & IEPF | 67,32,511 | 6.01% |
| NBFCs registered with RBI | 2,500 | 0.00% |
| Total Issued Share Capital | 11,19,26,800 | 100.00% |
🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
| Entity Name | Relationship | Country of Incorporation | % Shareholding | FY 2025-26 Revenue (₹ Crores) | FY 2025-26 PAT (₹ Crores) |
|---|---|---|---|---|---|
| Advanced Bio-Agro Tech Limited (ABTL) | Direct Subsidiary | India | 60.00% | 55.60 | 6.57 |
| JC Biotech Private Limited | Direct Subsidiary | India | 95.72% | 72.78 | 2.95 |
| SciTech Specialities Private Limited | Direct Subsidiary | India | 51.00% | 66.94 | 4.49 |
| Advanced EnzyTech Solutions Limited | Direct Subsidiary | India | 100.00% | 17.13 | 1.37 |
| Saiganesh Enzytech Solutions Pvt. Ltd. | Direct Subsidiary | India | 50.00% | 15.70 | 2.21 |
| Advanced Nutrazyme Private Limited | Direct Subsidiary | India | 100.00% | 0.002 | -0.02 |
| Advanced Enzymes USA, Inc. (Consolidated) | Direct Subsidiary | USA | 100.00% | 212.22 | 78.37 |
| Cal-India Foods International (SEB) | Step-down Unit | USA | 100.00% | — | — |
| AST Corporation | Step-down Unit | USA | 100.00% | — | — |
| Enzyme Innovation Inc. | Step-down Unit | USA | 100.00% | — | — |
| Starya Labs Inc. | Step-down Unit | USA | 100.00% | — | — |
| Advanced Enzymes Europe B.V. (Consolidated) | Direct Subsidiary | Netherlands | 100.00% | 31.92 | 2.54 |
| evoxx technologies GmbH | Step-down Unit | Germany | 100.00% | 31.92 | 4.98 |
Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities
AETL maintains a conservative, highly solvent balance sheet backed by prime credit ratings and robust bank banking relationships:
- Credit Ratings (ICRA Ratings):
- Long-Term Fund Based Cash Credit Limits: [ICRA]AA- (Stable)
- Long-Term / Short-Term Unallocated Limits: [ICRA]AA- (Stable) / [ICRA]A1+
- Short-Term Non-Fund Based Limits: [ICRA]A1+
- Banking Consortium: Key working capital and term loan banking relationships are maintained with Citibank N.A. and HDFC Bank Limited.
- Contingent Liabilities (Note 53): Total contingent claims against the Group not acknowledged as debts aggregate to ₹7.91 Crores as of March 31, 2026 (compared to ₹9.31 Crores in FY25), comprising:
- Income tax demand disputes under appeal: ₹5.23 Crores (against which tax deposits of ₹14.42 Crores have been paid/adjusted under protest).
- Excise duty and service tax disputes regarding CENVAT credit and product classification: ₹1.61 Crores.
- Fuel and Power Purchase Cost Adjustment (FPPCA) true-up claims by Andhra Pradesh DISCOMs (APERC order): ₹1.07 Crores.
- Capital Commitments: Estimated contract value of capital commitments remaining to be executed (net of advances) for plant expansion and R&D machinery stood at ₹38.99 Crores as of March 31, 2026.
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
Advanced Enzyme Technologies Limited possesses strong structural moats that protect its business model within the specialized biotechnology landscape:
- End-to-End Enzymology Integration: Unlike specialized marketing firms or contract fermenters, AETL controls the complete bio-manufacturing chain—from in-silico AI strain design, gene cloning, and submerged fermentation to downstream purification and final dosage formulation.
- Proprietary Strain Bank & IP Portfolio: Holds a biological library of over 68 proprietary micro-organisms, backed by 15 granted/pending patents, 400+ customized product formulations, and over 30 years of fermentation process optimization.
- Formidable Regulatory Moat: High regulatory barrier to entry established via 10 US FDA GRAS dossiers evaluated (with 7 ‘No Questions’ letters received), 17 food enzyme dossiers filed with the European Food Safety Authority (EFSA, with 13 positive opinions received), and REACH-ECHA registrations.
- Globally Competitive Cost Structure: Combining low-cost, high-yield fermentation scale in India with high-value technical support hubs in Europe and North America enables AETL to maintain consolidated gross margins of ~74% and EBITDA margins exceeding 30%.
What Could Go Wrong? Key Challenges & Business Risks
- Input Cost Volatility & Energy Costs: Fermentation processes are energy-intensive. Spikes in natural gas, coal, organic substrates (soy meal, wheat bran), packaging materials, and chemical solvents can compress operating margins.
- Geopolitical & Global Trade Disruptions: Tariffs, trade policy realignments, and shipping disruptions across critical maritime corridors (Red Sea, Strait of Hormuz) can elevate freight costs and delay export delivery cycles to American and European clients.
- Regulatory Delay Risk: Prolonged approval timelines for EFSA novel food dossiers or US FDA GRAS filings can delay commercial rollouts of new enzyme and probiotic strains.
- Foreign Exchange Volatility: With 50% of revenues derived from exports in US Dollars and Euros, sharp currency fluctuations impact net margin realisations.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
AETL is pursuing a calibrated growth strategy focused on geographical expansion, technological differentiation, and portfolio diversification:
- Biocatalysis Platform Scaling: Expanding the application of engineered enzymes as green alternatives to harsh chemical catalysts in active pharmaceutical ingredient (API) synthesis, fragrance manufacturing, and fine chemicals.
- B2C Consumer Wellness Expansion: Accelerating consumer marketing of the WELLFA brand through Advanced Nutrazyme Private Limited, targeting high-margin direct-to-consumer gut health, immune support, and effervescent wellness categories.
- New Central R&D Hub: Commissioning a state-of-the-art central R&D facility in Nashik during H2 FY 2026-27, featuring AI-driven in-silico enzyme design, high-throughput screening, and automated protein engineering platforms.
- Renewable Energy Adoption: Executing a group captive wind power collaboration (investing up to 26% equity in a Special Purpose Vehicle) to source up to 1.9 MW of clean wind energy for plants in Sinnar and Pithampur, lowering carbon intensity and operational energy costs.
The Verdict: Strategic Outlook & Conclusion
Advanced Enzyme Technologies Limited closed FY 2025-26 with record consolidated performance, generating ₹745.76 Crores in top-line revenue and ₹173.61 Crores in net profit. Supported by a net-cash balance sheet, ₹749.84 Crores in liquid treasury reserves, industry-leading 30%+ EBITDA margins, and an expanding global footprint across healthcare, agri-nutrition, and green industrial chemistry, AETL is well-positioned to capitalize on global supply chain diversification and the accelerating corporate shift toward bio-based, eco-friendly manufacturing solutions.
Frequently Asked Questions (FAQs) About Advanced Enzyme Technologies
Q1: What does Advanced Enzyme Technologies Limited manufacture and what are its core brands?
Advanced Enzyme Technologies Limited manufactures and markets over 400 proprietary enzyme products and probiotics across human healthcare, animal nutrition, food processing, non-food industrial bio-processing, and biocatalysis. Flagship products include the Serratiopeptidase API, DigeSEB® digestive complexes, SEBtilis™ and SEBclausii™ probiotics, and the WELLFA consumer wellness brand.
Q2: What were AETL’s revenue and net profit in FY 2025-26?
In FY 2025-26, AETL reported its highest-ever Consolidated Revenue from Operations of ₹745.76 Crores (up 17.09% YoY from ₹636.91 Crores in FY 2024-25) and a Consolidated Profit After Tax (PAT) of ₹173.61 Crores (up 29.59% YoY from ₹133.97 Crores in FY 2024-25).
Q3: Who are the promoters and key executives of the Company?
The Company was founded by Mr. Vasant L. Rathi (Chairman & Non-Executive Director) and late Mr. Chandrakant L. Rathi. Key executive leaders include Mr. Mukund M. Kabra (Whole-time Director), Mr. Beni Prasad Rauka (Group CFO), and Mr. Sanjay Basantani (Company Secretary & Head – Legal).
Q4: Where are AETL’s manufacturing facilities located and what is its export revenue contribution?
AETL operates 9 manufacturing facilities globally, including major Indian plants at Sinnar, Satpur, Vasind (Maharashtra), Pithampur SEZ (Madhya Pradesh), Ongole (Andhra Pradesh), and US plants in Chino, California. International sales/exports accounted for 50.03% (₹373.10 Crores) of total revenue in FY 2025-26.
Q5: What is AETL’s debt profile, credit rating, and net worth?
AETL operates a virtually debt-free balance sheet with total debt of ₹20.53 Crores against a Consolidated Net Worth of ₹1,683.12 Crores (Net Debt-to-Equity of 0.01x). ICRA has assigned the Company long-term credit ratings of [ICRA]AA- (Stable) and short-term ratings of [ICRA]A1+.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.advancedenzymes.com